Company intelligence / Profile preview

Attune Medical

Chicago, Illinois, United Stateshospital.haemonetics.com ↗

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

Attune Medical has developed and commercialized the ensoETM device for advanced patient temperature management. The product has received FDA clearance and regulatory approvals in multiple regions. It enables cost-effective and precise control of core body temperature to improve outcomes in critical care and surgical patients. The company was acquired by Haemonetics Corporation in April 2024 for $160 million upfront plus contingent payments based on sales growth.

Therapeutic areas: OtherCardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

ensoETM

Commercial

Indications: Esophageal protection during cardiac ablation

Partnerships

None specifically disclosed; now part of Haemonetics' portfolio.

Beyond the preview

Go deeper on Attune Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Attune Medical.

Explore the full profile